Not available
Quote | Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $0.1358 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 01/21/2020 04:31:27 pm |
News | Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA)
Following up on its initial announcements in January and February , Incyte (NASDAQ: INCY ) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2 , evaluating a topical cream formulation of kinase inhibitor ruxolitinib in adolescents and adults wi...
Quick Take Arcutis Biotherapeutics ( ARQT ) intends to raise $125 million from the sale of its common stock in an IPO, per an amended registration statement . The company is advancing a pipeline of treatment candidates for various skin conditions. For its lead candidate, ARQT plans to h...
Message Board Posts | Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Sienna Biopharmaceuticals Inc. Company Name:
SNNA Stock Symbol:
NASDAQ Market:
Sienna Biopharmaceuticals Inc. Website:
DULUTH, Ga. , Jan. 9, 2020 /PRNewswire/ -- Sebacia, Inc., a privately held commercial stage dermatology and aesthetics company, today provided a business update, first announcing an update to its leadership team. Mr. Chuck Abraham has been appointed Chief Executive Officer to lead ...
The biotech sector has been one of the high growth spaces over the past decade or so. It remains one of the hottest sectors for stock market investors. When a particular sector has the potential for expansion than even smaller companies, like penny stocks , in the sector have growth opportuniti...
WESTLAKE VILLAGE, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, on November 13, 2019, the United States Bankruptcy Court for the District of D...